

RECEIVED
CENTRAL FAX CENTER

Fax

APR 03 2006

Lilly

Eli Lilly and Company
Lilly Corporate Centre
Indianapolis, Indiana 46285
U.S.A.

Date: 3 April 2006

To:	D. Jiang	From:	Greg Cox
Company:	USPTO	Fax:	317-276-5172
Fax:	571-273-8300	Phone:	317-277-2620
	Technology Center 1600	Total Pages:	5

Privileged and Confidential Communication

RE: Serial No. 10/679,746
Group Art Unit: 1646
Confirmation: 8224
Docket No.: X-11921A

CONFIDENTIALITY NOTICE: This fax message from Eli Lilly and Company (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply fax and destroy all copies of the original message.

Please contact Jan Fowler at 317-655-1715 if you incur any difficulties with this transmission.

Answers That Matter.

RECEIVED
CENTRAL FAX CENTER

APR 03 2006

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

JANET FOWLER

Type or print name of person signing certification

Signature

4/3/06
Date

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Yakubu-Madus, et al.)
Serial No. : 10/679,746)
Filed : October 6, 2003) Group Art Unit: 1646
For : Synergistic use of Thiazolidinediones)
with Glucagon-Like Peptide- I and) Examiner: D. Jiang
Agonists Thereof to Treat Metabolic)
Instability Associated with Non-Insulin) Confirmation: 8224
Dependent Diabetes)
Docket No. : X-11921A)

RESPONSE TO RESTRICTION AND/OR ELECTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Election Requirement was set forth in an Office Action mailed March 7, 2006 for the patent application captioned above.

Claims 23-47 are pending in the present application.

Applicants respectfully request that the Examiner consider the following arguments against a restriction requirement.

Claims are reproduced for the Examiner's convenience and begin on page 2 of this paper.

Remarks begin on page 4 of this paper.